Loading data for AZN — first visit, this takes a few seconds.
AstraZeneca (AZN)
NYSE: AZN
· Real-Time Price · USD
160.10
+3.21 (2.05%)
At close: Aug 18, 2026, 8:00 PM
AstraZeneca (AZN) Stock Price, Analysis & Data
2.05% (1D)
No data available
| Bid | n/a |
| Market Cap | 248.3B |
| Revenue (ttm) | 61.37B |
| Net Income (ttm) | 10.45B |
| Beta | 0.21 |
| EPS (ttm) | 6.82 |
| PE Ratio (ttm) | 23.48 |
| Forward PE | 13.83 |
| P/B (ttm) | 4.94 |
| P/S (ttm) | 4.05 |
| Earnings Date | Oct 30, 2026 |
| Ask | n/a |
| Volume | 3,001,185 |
| Avg. Volume (20D) | 2,915,137 |
| Open | 159.12 |
| Previous Close | 156.89 |
| Day's Range | 158.98 - 160.64 |
| 52-Week Range | 145.80 - 212.71 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | $3.2 (2%) |
| Ex-Dividend Date | Aug 7, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormin...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date May 12, 1993
Employees 96,100
Stock Exchange NYSE
Ticker Symbol AZN
Website https://www.astrazeneca.com
Financial Performance
In 2025, AstraZeneca's revenue was 58.74B, an increase of 8.63% compared to the previous year's 54.07B. Earnings were 10.22B, an increase of 45.34%.
Financial StatementsEarnings Surprise
AstraZeneca has released their quarterly earnings on Jul 27, 2026:
AstraZeneca is scheduled to release its earnings on Oct 30, 2026, after market closes.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2